Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
第2相
早期終了
NCT05167409
| 対象疾患 | Microsatellite Stable Metastatic Colorectal Cancer |
|---|
| 相 | 第2相 |
|---|
| スポンサー | University of Colorado, Denver |
|---|
| ステータス | 早期終了 |
|---|
| 参加者数 | 19 名 |
|---|
| 介入（薬剤） | Evorpacept (ALX148), Cetuximab, Pembrolizumab |
|---|
| 開始日 | 2022年7月28日 |
|---|
| 完了日 | 2024年10月30日 |
|---|
| 結果公開日 | 2026年7月22日 |
|---|
概要
This Phase 2 clinical study will evaluate evorpacept (ALX148) in combination with cetuximab and pembrolizumab for refractory microsatellite stable metastatic colorectal cancer
Objective Response Rate (ORR)
The duration of time during which tumor assessments were performed for each individual patient. Per protocol, assessments will continue until disease progression. The latest assessment was performed at Cycle 21, Day 15 (14.5 mo after informed consent) · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 1 Participants |
|---|
Determine the Recommended Dose (RD) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab
During the safety run-in, each patient must have completed at least the 1st cycle (3 weeks) of treatment. · Participants
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 10 mg/kg Weekly | 0 Participants |
|---|
| Experimental: Stage 1: Safety run-in Evaluating Evorpacept at 15 mg/kg Weekly | 1 Participants |
|---|
| Experimental: Stage 2: Expansion Cohort Using Recommended Dose (RD) of Evorpacept | 0 Participants |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。